Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation.

Autor: Sameeh MY; Chemistry Department, Faculty of Applied Science, Umm El Qura Branch, Makkah 24211, Saudi Arabia., Khowdiary MM; Chemistry Department, Faculty of Applied Science, Umm El Qura Branch, Makkah 24211, Saudi Arabia.; Applied Surfactant Laboratory, Egyptian Petroleum Research Institute, Nasr City, Cairo 11727, Egypt., Nassar HS; Department of Chemistry, Faculty of Science and Arts in Al-Mukhwah, Al-Baha University, Al Bahah 65311, Saudi Arabia.; Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo 11884, Egypt., Abdelall MM; Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo 11884, Egypt., Amer HH; Department of Animal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City 32958, Egypt.; Department of Chemistry, Turabah University College, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia., Hamed A; Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo 11884, Egypt., Elhenawy AA; Department of Chemistry, Faculty of Science and Arts in Al-Mukhwah, Al-Baha University, Al Bahah 65311, Saudi Arabia.; Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo 11884, Egypt.
Jazyk: angličtina
Zdroj: Molecules (Basel, Switzerland) [Molecules] 2022 Jan 27; Vol. 27 (3). Date of Electronic Publication: 2022 Jan 27.
DOI: 10.3390/molecules27030830
Abstrakt: This work aimed to synthesize a new antihyperglycemic thiazolidinedione based on the spectral data. The DFT\B3LYP\6-311G** level of theory was used to investigate the frontier molecular orbitals (FMOs), chemical reactivity and map the molecular electrostatic potentials (MEPs) to explain how the synthesized compounds interacted with the receptor. The molecular docking simulations into the active sites of PPAR- γ and α -amylase were performed. The in vitro potency of these compounds via α -amylase and radical scavenging were evaluated. The data revealed that compounds ( 4 - 6 ) have higher potency than the reference drugs. The anti-diabetic and anti-hyperlipidemic activities for thiazolidine-2,4-dione have been investigated in vivo using the alloxan-induced diabetic rat model along with the 30 days of treatment protocol. The investigated compounds didn't show obvious reduction of blood glucose during pre-treatments compared to diabetic control, while after 30 days of treatments, the blood glucose level was lower than that of the diabetic control. Compounds ( 4 - 7 ) were able to regulate hyperlipidemia levels (cholesterol, triglyceride, high-density lipoproteins and low- and very-low-density lipoproteins) to nearly normal value at the 30th day.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje